"WASHINGTON -- The FDA approved selpercatinib (Retevmo) as the first specific treatment for metastatic non-small cell lung cancer (NSCLC) or thyroid cancer with rearranged during transfection (RET) gene fusions.
A selective inhibitor of the RET kinase, selpercatinib received the indication through FDA's accelerated approval process, which requires the sponsor, Eli Lilly, to conduct additional studies to confirm the safety and efficacy of the drug as a condition of final approval."
Written by
vocalEK
To view profiles and participate in discussions please or .
I am sorry that you do not appear to have received a timely response to your post/question - or perhaps you got an answer on another post or in a Private Message? Please feel free to post a new question if you wish. Posts are sometimes missed as it is so busy. Or maybe no-one who read it was able to answer?
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Would love some advice
Interaction between thyroid meds and ADHD meds 
Eyebrows have started growing again : )
Need Advice Please 
